CeriBell (NASDAQ:CBLL) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of CeriBell (NASDAQ:CBLLFree Report) in a research note released on Tuesday, MarketBeat Ratings reports. The firm issued an overweight rating and a $32.00 price target on the stock.

CBLL has been the topic of several other research reports. TD Cowen began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $31.00 target price on the stock. William Blair initiated coverage on CeriBell in a research note on Tuesday. They set an “outperform” rating on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.00.

Read Our Latest Stock Analysis on CBLL

CeriBell Stock Down 2.3 %

Shares of NASDAQ:CBLL opened at $28.27 on Tuesday. CeriBell has a 52 week low of $23.00 and a 52 week high of $29.53.

CeriBell Company Profile

(Get Free Report)

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Read More

Analyst Recommendations for CeriBell (NASDAQ:CBLL)

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.